Lifetime Management in Low- And Intermediate-Risk TAVI: Insights on Navitor and the VANTAGE Data | N. Van Mieghem
Discover why safety, durability, optimal hemodynamics and future coronary access are key when treating low- and intermediate-risk TAVI patients. Don't miss N. Van Mieghem reviewing the VANTAGE trial and Navitor™, highlighting very low one-year mortality and disabling stroke, no moderate or severe PVL and excellent valve haemodynamics.
LEARN MORE:
Related Videos
Procedural tip & tricks with Navitor across all valve sizes
Transcatheter Aortic Valves Implant
1-year VANTAGE TAVI outcomes in low/intermediate-risk patients
A Defining Moment Has To Start Somewhere. Why Not With You?
Webinar for Collaborative Management of HF Patients with MR
Transcatheter tricuspid valve repair: Cases, tips and tricks
M-TEER: Best treatment strategies for FMR AND DMR
Latest evidence in patient selection for T-TEER
TRENDING TOPICS
Procedural tip & tricks with Navitor across all valve sizes
1-year VANTAGE TAVI outcomes in low/intermediate-risk patients
Transcatheter Aortic Valves Implant
